Transcriptomics

Dataset Information

0

Gene and miRNA expression profiles in Polycythemia Vera and Essential Thrombocythemia according to CALR and JAK2 mutations [GEP]


ABSTRACT: Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferative neoplasms (MPNs) characterized by erythrocytosis and thrombocytosis, respectively. Approximately 95% of PV and 50–70% of ET patients harbour the V617F mutation in the exon 14 of JAK2 gene, while about 20-30% of ET patients carry CALRins5 or CALRdel52 mutations. These ET CARL-mutated subjects show higher platelet count and lower thrombotic risk compared to JAK2-mutated patients. Here we showed that CALR-mutated and JAK2V617F-positive CD34+ cells have different gene and miRNA expression profiles. Indeed, we highlighted several pathways differentially activated between JAK2V617F- and CALR-mutated progenitors, i.e. mTOR, MAPK/PI3K and MYC pathways. Furthermore, we unveiled that the expression of several genes involved in DNA repair, chromatin remodelling, splicing and chromatid cohesion are decreased in CALR-mutated cells. According to the low risk of thrombosis in CALR-mutated patients, we also found the down-regulation of several genes involved in thrombin signalling and platelet activation. As a whole, these data support the model in which CALR-mutated ET could be considered as a distinct disease entity from JAK2V617F-positive MPNs and may provide the molecular basis supporting the different clinical features of these patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103237 | GEO | 2018/03/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-03-01 | GSE103238 | GEO
2014-06-03 | E-GEOD-54644 | biostudies-arrayexpress
2018-10-29 | GSE120362 | GEO
2013-07-23 | E-GEOD-41812 | biostudies-arrayexpress
2013-07-23 | GSE41812 | GEO
2014-06-03 | E-GEOD-54645 | biostudies-arrayexpress
2018-10-29 | GSE120363 | GEO
2018-08-06 | E-MTAB-6878 | biostudies-arrayexpress
2021-09-07 | PXD026803 | Pride
2024-09-01 | GSE269568 | GEO